Antares Pharma to Host Fourth Quarter 2014 Operating and Financial Results Conference Call

Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its fourth quarter 2014 financial results before the market opens on Thursday, March 12, 2015, and host a conference call shortly thereafter at 8:30 a.m. ET (Eastern Time) to discuss the results. Eamonn P. Hobbs, President and Chief Executive Officer, Robert F. Apple, EVP, Chief Operating Officer, and James E. Fickenscher, Senior Vice President, Chief Financial Officer, will host the call.

Interested parties may participate in the conference call by dialing 1-888-455-2296 (U.S.) or 1-719-325-2455 (international) 5 to 10 minutes prior to the start of the call. The conference access code is 8802999. A replay of the conference call will be available from 11:30 a.m. ET on Thursday, March 12, 2015 through 11:30 a.m. ET on Friday, March 27, 2015 by dialing 1-888-203-1112 (U.S.) or 1-719-457-0820 (international), and entering the access code 8802999. An audio web cast and archive of the conference call will also be available under the investor information section of the Antares Web site at www.antarespharma.com.

About Antares Pharma

Antares Pharma focuses on self-administered parenteral pharmaceutical products. The Company markets OTREXUP™ (methotrexate) injection for subcutaneous use in the treatment of adults with severe active rheumatoid arthritis and children with active polyarticular juvenile idiopathic arthritis. LEO Pharma markets OTREXUP™ to dermatologists for adults with severe recalcitrant psoriasis. Antares Pharma is also developing QuickShot® Testosterone for testosterone replacement therapy, and VIBEX® Sumatriptan for the acute treatment of migraines. The Company's technology platforms include VIBEX® disposable auto injectors, disposable multi-use pen injectors and reusable needle-free injectors. Antares Pharma has a multi-product deal with Teva Pharmaceutical Industries, Ltd. that includes VIBEX® epinephrine, exenatide multi-dose pen, and another undisclosed multi-dose pen. Our reusable needle-free injector for use with human growth hormone (hGH) is sold worldwide by Ferring Pharmaceuticals BV.